The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities during the period of July 30, 2025 through February 24, 2026, inclusive (“the Class Period”). Investors are encouraged to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
If you suffered a loss on your Beta Bionics investments, you have until November 3, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this deadline. If you choose to take no action, you may remain an absent class member. For more information about the lawsuit:
[CONTACT THE FIRM IF YOU SUFFERED A LOSS]
What Is This Lawsuit About? The lawsuit alleges that Beta Bionics made false and/or misleading statements and failed to disclose to investors that: (i) the Company’s iLet Bionic Pancreas insulin pump (“iLet”) was malfunctioning and dosing patients with dangerously high levels of insulin, causing hypoglycemic events; (ii) the FDA had raised these issues in a Form 483 it sent to Beta Bionics; (iii) there were thousands of customer complaints back-filed with the FDA in response to the Form 483, including hundreds of life-threatening events requiring significant medical intervention; and (iv) the FDA was not satisfied with the Company’s response to the issue, as Beta Bionics had failed to implement meaningful corrective actions.
On January 8, 2026, Beta Bionics reported its fourth quarter 2025 earnings results, revealing an unexpected miss on new iLet patient starts. On this news, Beta Bionics’ stock price dropped $11.85, or 37%, to close at $20.14 per share on January 9, 2026.
On January 30, 2026, Beta Bionics filed a Form 8-K with the U.S. Securities & Exchange Commission, revealing that the FDA had sent the Company a warning letter connected to its earlier Form 483. The Company revealed that the FDA’s concerns were more serious than they had previously acknowledged, and that the FDA took issue with Beta Bionics’ quality management system for iLet and the Company’s failure to take corrective action based on the Form 483. On this news, Beta Bionics’ stock price fell $0.96, or 6.5%, to close at $13.83 per share on January 30, 2026.
Then, on February 24, 2026, the FDA publicly released its warning letter, revealing the FDA’s concerns with iLet’s underlying issues and stating that any iLet malfunction or hypoglycemia requiring medical intervention must be reported to the FDA. On this news, Beta Bionics’ stock price fell $0.50, or 3.7%, to close at $12.89 per share on February 25, 2026.
[LEARN MORE ABOUT THE LAWSUIT]
The Lead Plaintiff Appointment Process. The federal securities laws permit any investor who acquired eligible securities during the class period to seek appointment as lead plaintiff in a class action lawsuit. Learn more about the lead plaintiff process and eligibility requirements here. Courts typically appoint the investor(s) with the largest financial loss in the case and the ability to represent the class rather than investors with simply the largest investment portfolio. Courts regularly appoint individual investors, whether acting alone or as a group, as lead plaintiffs. The rights of any investor who bought shares during the class period are generally already protected. However, lead plaintiffs have the power to influence case strategy and have a say in settlement decisions, as well as decisions concerning allocation of settlement funds among class members.
[LEARN MORE ABOUT THE LEAD PLAINTIFF PROCESS]
What Should I Do? If you purchased or otherwise acquired Beta Bionics securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260908726483/en/
Media gallery
